References
- Swedberg K, Komajda M, Bohm M et al.; on behalf of the SHIFT investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet376, 875–885 (2010).
- Zannad F, McMurray JJV, Krum H et al.; the EMPHASIS-HF study group. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. DOI: 10.1056/NEJMoa1009492 (2010) (Epub ahead of print).
- Jacobson AF, Senior R, Cerqueira MD et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J. Am. Coll. Cardiol.55, 2212–2221 (2010).
- Boogers MJ, Borleffs CJ, Hennemann MM et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients J. Am. Coll. Cardiol.55, 2769–2777 (2010).
- Damman K, Van Veldhuisen DJ, Navis G et al. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart96, 1297–1302 (2010).
- Inglis SC, Clark RA, McAlister FA et al. Structured telephone support or telemonitoring programmes for patients with chronic heart failure. Cochrane Database System. Rev.8, CD007228 (2010).